Our attorneys have filed a mass tort lawsuit on behalf of individuals who took the blood clot medication xarelto
thinner Xarelto (rivaroxaban) and suffered significant bleeding events. Pharmaceutical firms, such as the makers of Xarelto, possess a duty to make sure that their drugs are reasonably secure for use - and failure to do so might be grounds for compensation. Our lawyers are working difficult to obtain those hurt by the drug the compensation they are entitled to.
Although bleeding is a widespread complication linked with anticoagulants, it has been alleged that Xarelto is much more hazardous than standard blood thinners simply because no antidote exists to reverse its blood-thinning effects. This signifies that, in the occasion of an emergency, patients may possibly be at threat for irreversible bleeding issues, which includes life-threatening internal and gastrointestinal hemorrhaging.
Should you or perhaps a loved one suffered a severe bleeding event after taking Xarelto, you might have legal recourse. For much more data, speak to us these days to have your case reviewed, free of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are in search of compensation from Bayer and Janssen for past and future health-related bills, lost wages, discomfort and suffering and, in situations of death, funeral expenditures. In addition, they're seeking punitive damages, which are normally awarded to punish the defendant and deter other organizations from acting similarly.
Why Are Lawsuits Getting Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is harmful and defective. The plaintiffs claim that, unlike traditional anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning
effects can be reversed using vitamin K, there is no antidote available for Xarelto. Because of this, the lawsuits claim, doctors have no effective means of stopping Xarelto users from bleeding within the event of an emergency. Plaintiffs in the lawsuits allege critical and fatal injuries, such as cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior inside the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and health-related staff were not properly made aware of methods to stabilize and treat a Xarelto user in the occasion of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding occasion.
Xarelto is linked to critical bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal
bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing hazardous clotting.
Visit this page for more information on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys in the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.